NCT07543731Recruiting
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy
Source: ClinicalTrials.gov · Last updated 15 Jul 2026
Brief summary (registry, in English)
This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5995 (estimated)
- First submitted
- 14 Apr 2026
- Start date
- 2 Apr 2026
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT07543731
What you commit to
- Study type: Observational
- Planned participants: 5995
- From 2 Apr 2026 to the primary completion date, 30 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.
Who the study is looking for
- A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.
- Age ≥18 years at index date.
- With at least 12 months data availability prior to index date.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Coordinator of this site? Confirm its status | Basel | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.